Europese Unie - Nederlands - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - belatacept - graft rejection; kidney transplantation - immunosuppressiva - nulojix, in combination with corticosteroids and a mycophenolic acid (mpa), is indicated for prophylaxis of graft rejection in adult recipients of a renal transplant.

Europese Unie - Nederlands - EMA (European Medicines Agency)

novartis europharm limited - basiliximab - graft rejection; kidney transplantation - immunosuppressiva - simulect is geïndiceerd voor de profylaxe van acute orgaanafstoting bij de novo allogene niertransplantatie bij volwassen en pediatrische patiënten (1-17 jaar). het is om te worden gebruikt samen met ciclosporine voor microemulsion - en corticosteroïd-gebaseerde immunosuppressie, bij patiënten met een panel-reactieve antilichamen minder dan 80%, of een drie-onderhoud immunosuppressief regime met ciclosporine voor microemulsion, corticosteroïden en azathioprine of mycofenolaat mofetil.

Europese Unie - Nederlands - EMA (European Medicines Agency)

hansa biopharma ab - imlifidase - desensitization, immunologic; kidney transplantation - immunosuppressiva - idefirix is indicated for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. the use of idefirix should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients.

Europese Unie - Nederlands - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - graft rejection - immunosuppressiva - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

glaxosmithkline consumer healthcare b.v. van asch van wijckstraat 55g 3811 lp amersfoort - fluticasonpropionaat 0,5 mg/ml - neusspray, suspensie - benzalkoniumchloride ; carmellose natrium (e 466) ; cellulose, microkristallijn (e 460) ; fenylethylalcohol ; glucose 0-water ; polysorbaat 80 (e 433) ; water, gezuiverd, - fluticasone

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

haleon belgium sa-nv - fluticasonpropionaat 0,05 % w/w - neusspray, suspensie - 50 µg/dose - fluticasonpropionaat 50 µg/dosis - fluticasone

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

fresenius kabi nederland b.v. amersfoortseweg 10 e 3712 bc huis ter heide - carboplatine 10 mg/ml - concentraat voor oplossing voor infusie - water voor injectie, - carboplatin

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

fresenius kabi sa-nv - carboplatine 10 mg/ml - concentraat voor oplossing voor infusie - 10 mg/ml - carboplatine 10 mg/ml - carboplatin

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

fresenius kabi sa-nv - carboplatine 10 mg/ml - concentraat voor oplossing voor infusie - 10 mg/ml - carboplatine 10 mg/ml - carboplatin

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

fresenius kabi sa-nv - carboplatine 10 mg/ml - concentraat voor oplossing voor infusie - 10 mg/ml - carboplatine 10 mg/ml - carboplatin